The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.
Presynaptic antiseizure medications-basic mechanisms and clues for their rational combinations
Open accessAbstract
Among clinically highly efficient antiseizure medications (ASMs) there are modifiers of the presynaptic release machinery. Of them, levetiracetam and brivaracetam show a high affinity to the synaptic vesicle protein type 2 A (SV2A), whereas pregabalin and gabapentin are selective ligands for the α2δ1 subunits of the voltage-gated calcium channels. In this paper, we present recent progress in understanding the significance of presynaptic release machinery in the neurochemical mechanisms of epilepsy and ASMs. Furthermore, we discuss whether the knowledge of the basic mechanisms of the presynaptically acting ASMs might help establish a rational polytherapy for drug-resistant epilepsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 The main neuronal targets of racetams and gabapentinoids (inspired by the figure in the paper by Bialer and White [166])](https://figures.cochat.ai/paper-figures/214bd69aa7d24435a3fffecf5c6f060f/presynaptic-antiseizure-medications-basic-mechanisms-and-clues-for-their-figure-1.jpg)
![Fig. 2 Isobolograms illustrating interactions between gabapentin and pregabalin in the 6 Hz corneal stimulation-induced seizure (A) and maximal electroshock-induced (MES) seizure (B) tests in mice. A. The type I isobolographic analysis was used to assess the interactions between two fully effective drugs in the mouse 6 Hz test (A). The isobologram for the combination of two fully active drugs, pregabalin and gabapentin in the 6 Hz test was presented earlier [77], and partly modified to display isobolographically areas of synergy, additivity and antagonism, where the experimentally derived ED50 mix value can be placed. The ED50 values for pregabalin and gabapentin when used alone in the 6 Hz test are placed on the ordinate (Y) and abscissa (X) of the Cartesian plot system of coordinates, respectively. The line connecting these ED50 values on the X and Y axes is the line of additivity. The diagonal line starting from the beginning of the Cartesian plot system and crossing the line of additivity indicates the proportion of the two-drug mixture (at the fixed-ratio of 1:1). For the interaction of pregabalin with gabapentin in the 6 Hz test, the experimentally derived ED50 mix (as the point M on the graph) is placed in the area of additivity, close to the point A, which reflects the theoretically calculated ED50 add value, predicted to exert additive interaction between drugs. B. The type II isobolographic analysis was conducted to evaluate the interaction between drugs of which gabapentin was ineffective in the mouse MES test (B). The isobologram for the combination of pregabalin (a fully active drug) and gabapentin (a virtually ineffective drug) in the MES test was presented earlier [130], and partly modified to display isobolographically areas of synergy, additivity and antagonism, where the experimentally derived ED50 mix value can be placed. The ED50 value for pregabalin when used alone in the mouse MES test is placed on the ordinate of the Cartesian plot system of coordinates. The line parallel to X axis starting from the ED50 for pregabalin is the line of indifference (additivity). The diagonal lines starting from the beginning of the Cartesian plot system and crossing the line of additivity indicate the proportions of the drugs in the mixture (at the fixed-ratios of 1:1, 1:2 and 1:4). For the interaction of pregabalin with gabapentin in the MES test, the experimentally derived ED50 mix (as the point M on the graph for the fixed-ratio of 1:1) is placed in the area of synergy, significantly below the area of additivity (*p < 0.05), which reflects the theoretically calculated ED50 add value, predicted to exert additive interaction between drugs](https://figures.cochat.ai/paper-figures/ace3fa425a3d4a298f861b3fb78b7ba8/presynaptic-antiseizure-medications-basic-mechanisms-and-clues-for-their-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Functionally, SV2A modulation limits the slide from induced plasticity to maladaptive remodeling and relapse-like behavior [175,199,205].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [205]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“After ketamine or other plasticity-promoting interventions, preserving vesicle cycling and maintaining a competent readily releasable pool appear crucial for sustaining gains; animal studies link antidepressant durability to synaptic integrity supported by SV2A pathways and complementary signaling through ERK and calcium channels [199,201,205].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [205]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“After ketamine or other plasticity-promoting interventions, preserving vesicle cycling and maintaining a competent readily releasable pool appear crucial for sustaining gains; animal studies link antidepressant durability to synaptic integrity supported by SV2A pathways and complementary signaling through ERK and calcium channels [199,201,205].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [205]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conceptually, SV2A enhancers complement plasticity modulators by securing the presynaptic substrate needed to translate spine growth into durable circuit performance, a metaplasticity framework that aims to extend remission and minimize recurrence across neuropsychiatric disorders [205,226].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [205]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Levetiracetam analogs and newer SV2A enhancers are attractive maintenance-phase adjuncts because they directly stabilize presynaptic function after induction therapies [175,199,205].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [205]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thijs, R. D., Surges, R., O'Brien, T. J., & Sander, J. W. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32596-0 · Cited by 2,183
The synaptic vesicle cycle: a cascade of protein–protein interactions
Südhof, T. C. (1995) · Nature · doi:10.1038/375645a0 · Cited by 1,989 · cited 1×
“This hypothesis has been supported by electrophysiological studies which demonstrated that sv2a deletion reduces the action of the potential-dependent release of GABA in the CA3 region of SV cycle have been identified and their role partially unrav - eled [25 ].”
ResultSöllner, T., Bennett, M. K., Whiteheart, S. W., Scheller, R. H., & Rothman, J. E. (1993) · Cell · doi:10.1016/0092-8674(93)90376-2 · Cited by 1,896 · cited 1×
“Several synaptic proteins such as synapto-brevin, vesicle-associated SNARE (v-SNARE), and two target or plasma membrane SNAREs (t-SNAREs), synapto-somal associated protein 25 (SNAP25) and syntaxin form a stable complex that is probably engaged in both SV docking and fusion [26].”
BackgroundThe synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 2×
“Lynch et al. (2004) first provided several lines of evidence that the synaptic vesicle protein SV2A was the binding site for levetiracetam ((S)-alpha- ethyl-2-oxo-pyrrolidine acetamide).”
BackgroundBerenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Jasper's Basic Mechanisms of the Epilepsies
(2012) · Oxford University Press eBooks · doi:10.1093/med/9780199746545.001.0001 · Cited by 1,143
Neher, E. (1998) · Neuron · doi:10.1016/s0896-6273(00)80983-6 · Cited by 1,010
Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., Cramp, C., Cockerell, O. C., Cooper, P. N., Doughty, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60460-7 · Cited by 976 · cited 1×
“However, in a large comparative study, gabapentin was found to be less effective than lamotrigine [ 144].”
BackgroundLöscher, W. (2011) · Seizure · doi:10.1016/j.seizure.2011.01.003 · Cited by 932
Löscher, W., Potschka, H., Sisodiya, S. M., & Vezzani, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019539 · Cited by 903
EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892 · cited 1×
“Gabapentin is also used off-label for generalized anxiety disorder and panic disorder, obsessive-compulsive disorder, addictions, bipolar disorder, essential tremor, and migraine prophylaxis [ 142, 143].”
BackgroundA Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin
Bockbrader, H. N., Wesche, D., Miller, R., Chapel, S., Janiczek, N., & Burger, P. (2010) · Clinical Pharmacokinetics · doi:10.2165/11536200-000000000-00000 · Cited by 690 · cited 1×
“The distribution of the drug and its non-linear absorption pharmaco-kinetics requires its dosing three times daily [145].”
BackgroundMechanisms of epileptogenesis and potential treatment targets
Pitkänen, A., & Lukasiuk, K. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70310-0 · Cited by 614 · cited 1×
“Since epilepsy and epilepto-genesis seem to be connected with the pathological transformation of neuronal circuits [21], drugs that interfere with molecular mechanisms of synaptic plasticity merit special attention [22].”
BackgroundPharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy
Barton, M. E., Klein, B. D., Wolf, H. H., & Steve White, H. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00302-3 · Cited by 613 · cited 1×
“…may be ascribed to different seizure models– for instance, the results from MES may have the best predictive value for generalized tonic-clonic seizures [163], from the PTZ test– for myoclonic and to a certain degree for absences [164], and from 6-Hz– for drug-resistant focal seizures [165].”
BackgroundMolecular Targets of Cannabidiol in Neurological Disorders
Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 578
Tomson, T., Battino, D., Bonizzoni, E., Craig, J., Lindhout, D., Perucca, E., Sabers, A., Thomas, S. V., Vajda, F., Faravelli, F., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30107-8 · Cited by 544 · cited 1×
“Along with lamotrigine and oxcarbazepine, it is also one of the safest ASMs used in the treatment of women at the childbearing age, with the potential teratogenic effect within the range of the population risk of major congenital defects [86–88 ].”
BackgroundKey factors in the discovery and development of new antiepileptic drugs
Bialer, M., & White, H. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2997 · Cited by 542
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
Klitgaard, H., Matagne, A., Gobert, J., & Wülfert, E. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00410-5 · Cited by 506 · cited 1×
“Furthermore, levetiracetam displayed a very high safety margin in animal models of seizures [65].”
BackgroundCharacterization of ethosuximide reduction of low‐threshold calcium current in thalamic neurons
Coulter, D. A., Huguenard, J. R., & Prince, D. A. (1989) · Annals of Neurology · doi:10.1002/ana.410250610 · Cited by 504
Mechanisms of action of currently used antiseizure drugs
Sills, G. J., & Rogawski, M. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107966 · Cited by 489 · cited 3×
“…an inhibitor of excitatory neurotrans - mission, an inhibitor of carbonic anhydrase and possibly a modulator of the voltage-and receptor-gated calcium ion channels) and stiripentol (a positive allosteric modulator of the GABA A R which also interferes with GABA reuptake and metabolism) [15, 16].”
BackgroundDe Novo Mutations in Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies
Appenzeller, S., Balling, R., Barisic, N., Baulac, S., Caglayan, H., Craiu, D., De Jonghe, P., Depienne, C., Dimova, P., Djémié, T., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.08.013 · Cited by 439
Patsalos, P. N., & Perucca, E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00409-5 · Cited by 423 · cited 1×
“This is facilitated by the fact that representatives of both these groups are characterized by the lowest interaction potential among all ASMs [157].”
BackgroundAbnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415 · cited 3×
“This hypothesis might contradict the fact that the absence of SV2A in mice led to an epileptic phenotype [41 ], but the elevated expression of SV2 was also reported to result in a neurotransmission phenotype that resembled that seen in SV2 KO neurons [ 49] suggesting that either too little or too…”
BackgroundResultInfluentialLöscher, W., Hönack, D., Fassbender, C. P., & Nolting, B. (1991) · Epilepsy Research · doi:10.1016/0920-1211(91)90062-k · Cited by 403
Mechanisms of Action of Antiepileptic Drugs
Czapinski, P., Blaszczyk, B., & Czuczwar, S. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053386962 · Cited by 382 · cited 1×
“…an inhibitor of excitatory neurotrans - mission, an inhibitor of carbonic anhydrase and possibly a modulator of the voltage-and receptor-gated calcium ion channels) and stiripentol (a positive allosteric modulator of the GABA A R which also interferes with GABA reuptake and metabolism) [15, 16].”
BackgroundSelf-citationLamotrigine substitution study: evidence for synergism with sodium valproate?
Brodie, M. J., & Yuen, A. W. C. (1997) · Epilepsy Research · doi:10.1016/s0920-1211(96)01007-8 · Cited by 379
Epilepsy—Definition, Classification, Pathophysiology, and Epidemiology
Falco-Walter, J. (2020) · Seminars in Neurology · doi:10.1055/s-0040-1718719 · Cited by 370
SV2A and SV2B Function as Redundant Ca2+ Regulators in Neurotransmitter Release
Janz, R., Goda, Y., Geppert, M., Missler, M., & Südhof, T. C. (1999) · Neuron · doi:10.1016/s0896-6273(00)81046-6 · Cited by 367
Löscher, W. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2222-z · Cited by 367
Löscher, W., & Klein, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00827-8 · Cited by 367 · cited 1×
“Some of them block voltage-gated Na + channels (VGSCs) or voltage-gated Ca 2 + channels (VGCCs), increase GABA concentra - tions, block glutamate receptors, inhibit carbonic anhydrase, activate GABA A receptors (GABA A R) r or modulate synaptic vesicles [11].”
BackgroundSelection of Antiepileptic Drug Polytherapy Based on Mechanisms of Action: The Evidence Reviewed
Deckers, C. L. P., Czuczwar, S. J., Hekster, Y. A., Kewser, A., Kubova, H., Meinardi, H., Patsalos, P. N., Renier, W. O., & Van Rijn, C. M. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00111.x · Cited by 331 · cited 2×
“It appears that combining ASMs with various mechanisms of action is more efficacious than using combinations of ASMs sharing the same or comparable mechanisms [161].”
BackgroundSelf-citationPiracetam: A Review of Pharmacological Properties and Clinical Uses
Winblad, B. (2005) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00268.x · Cited by 317 · cited 1×
“The mechanism presumably comprises the restoration of cell membrane fluidity in elderly animals and humans, modulation of cholinergic and glutamatergic transmission, improvement of neuroplasticity, and facilitation of microcirculation [109 ].”
BackgroundGorter, J. A., van Vliet, E. A., Aronica, E., Breit, T., Rauwerda, H., Lopes da Silva, F. H., & Wadman, W. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2766-06.2006 · Cited by 316 · cited 1×
“To this end, the microarray study on ipsilateral hippocampal CA3 and entorhinal cortex showed that sv2a was transiently down - regulated in the entorhinal cortex during pilocarpine-induced epileptogenesis in rats [43 ].”
BackgroundIon Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies
Oyrer, J., Maljevic, S., Scheffer, I. E., Berkovic, S. F., Petrou, S., & Reid, C. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014456 · Cited by 315 · cited 1×
“…alterations in expression, loss-or gain-of-function mutations of protein subunits, polymorphisms, and cellular energetic deficits can all contribute to dysfunc - tion of the voltage-and ligand-dependent sodium, calcium, potassium, and chloride channels, eventually promoting seizure discharges [9 ].”
BackgroundInteractions between antiepileptic drugs, and between antiepileptic drugs and other drugs
Zaccara, G., & Perucca, E. (2014) · Epileptic Disorders · doi:10.1684/epd.2014.0714 · Cited by 305 · cited 1×
“The adjuvant drug should not have any adverse pharmacokinetic interactions with the first antiepileptic medication or other concomitant drugs [152].”
BackgroundMalykh, A. G., & Sadaie, M. R. (2010) · Drugs · doi:10.2165/11319230-000000000-00000 · Cited by 270
Gillard, M., Fuks, B., Leclercq, K., & Matagne, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.064 · Cited by 253
Xie, X., Lancaster, B., Peakman, T., & Garthwaite, J. (1995) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/bf00373920 · Cited by 249 · cited 1×
“Of the marketed ASMs, phenytoin, primidone, carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, rufinamide, and zonisamide bind to VGSCs in their state of fast inactivation (within milliseconds) and induce transient, voltage-and frequency-dependent reduction in the channel conductance [12 ].”
BackgroundIonotropic Glutamate Receptors in Epilepsy: A Review Focusing on AMPA and NMDA Receptors
Hanada, T. (2020) · Biomolecules · doi:10.3390/biom10030464 · Cited by 249 · cited 3×
“Levetiracetam is also recommended in the treatment of status epilepticus due to its availability in the intravenous formula [5–7].”
BackgroundChamberlain, J. M., Kapur, J., Shinnar, S., Elm, J., Holsti, M., Babcock, L., Rogers, A., Barsan, W., Cloyd, J., Lowenstein, D., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30611-5 · Cited by 238
Calandre, E. P., Rico-Villademoros, F., & Slim, M. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1202764 · Cited by 235 · cited 3×
“Treatment with gabapentinoids also poses a risk of abuse and dependence, especially in patients abusing other drugs and substances in the past [142, 146].”
BackgroundMatagne, A., Margineanu, D., Kenda, B., Michel, P., & Klitgaard, H. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.198 · Cited by 224 · cited 1×
“Matagne et al. (2008) conducted a comparative in vitro and in vivo study of the anti-seizure activity of brivaracetam and levetiracetam.”
BackgroundMarson, A., Burnside, G., Appleton, R., Smith, D., Leach, J. P., Sills, G., Tudur-Smith, C., Plumpton, C., Hughes, D. A., Williamson, P., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00246-4 · Cited by 219 · cited 1×
“…also been proven that the effectiveness of levetiracetam is lower than that of valpro - ate in the treatment of idiopathic generalized epilepsies [94] and lower than lamotrigine in the treatment of focal epilepsies [95 ], which puts into question its use as a first-line drug in the treatment of…”
BackgroundPreclinical Development of Antiepileptic Drugs: Past, Present, and Future Directions
White, H. S. (2003) · Epilepsia · doi:10.1046/j.1528-1157.44.s7.10.x · Cited by 212
Marson, A., Burnside, G., Appleton, R., Smith, D., Leach, J. P., Sills, G., Tudur-Smith, C., Plumpton, C., Hughes, D. A., Williamson, P., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00247-6 · Cited by 208 · cited 1×
“…that the effectiveness of levetiracetam is lower than that of valpro - ate in the treatment of idiopathic generalized epilepsies [94] and lower than lamotrigine in the treatment of focal epilepsies [95 ], which puts into question its use as a first-line drug in the treatment of epilepsy [96].”
BackgroundPathophysiogenesis of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic?
Curia, G., Lucchi, C., Vinet, J., Gualtieri, F., Marinelli, C., Torsello, A., Costantino, L., & Biagini, G. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867320666131119152201 · Cited by 207 · cited 1×
“Since epilepsy and epilepto-genesis seem to be connected with the pathological transformation of neuronal circuits [21], drugs that interfere with molecular mechanisms of synaptic plasticity merit special attention [22].”
BackgroundLevetiracetam: a review of its use in epilepsy.
Lyseng-Williamson, K. A. (2011) · PubMed · doi:10.2165/11204490-000000000-00000 · Cited by 194 · cited 1×
“…sound-sensitive mice derived from a DBA strain and in the Genetic Absence Epilepsy Rats from the Strasbourg [77]; b– results from [167]; c– results from [66]; d– results from [168]; e– results from [133]; f– results from [130] other drugs which makes it a suitable medication for the elderly [85 ].”
ResultGabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice
Chincholkar, M. (2020) · British Journal of Pain · doi:10.1177/2049463720912496 · Cited by 186
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184 · cited 1×
“Although SV2A is regarded as the primary molecular target for antiseizure effects of leveti - racetam and brivaracetam, new ligands of SV2A have been designed that show procognitive but not antiseizure properties [113 ].”
BackgroundKaminski, R. M., Matagne, A., Leclercq, K., Gillard, M., Michel, P., Kenda, B., Talaga, P., & Klitgaard, H. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.11.021 · Cited by 169 · cited 3×
“Thus, an intracortical injection of Kaminski et al. (2008) demonstrated that there is a strong correlation between the SV2A binding affinity of structur - ally diverse ligands and their anticonvulsant potency in vivo [48].”
BackgroundInfluentialNicolas, J., Hannestad, J., Holden, D., Kervyn, S., Nabulsi, N., Tytgat, D., Huang, Y., Chanteux, H., Staelens, L., Matagne, A., et al. (2016) · Epilepsia · doi:10.1111/epi.13267 · Cited by 169
Klitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13340 · Cited by 168
Kwan, P., Trinka, E., Van Paesschen, W., Rektor, I., Johnson, M. E., & Lu, S. (2014) · Epilepsia · doi:10.1111/epi.12391 · Cited by 164 · cited 1×
“Brivar - acetam also proves to be effective in generalized epilepsy; however, it is used off-label in keeping with this indication [99 ].”
BackgroundTrinka, E., & Leitinger, M. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001103 · Cited by 157
Yates, S. L., Fakhoury, T. A., Liang, W., Eckhardt, K., Borghs, S., & D’Souza, J. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.09.005 · Cited by 156 · cited 1×
“The results of observational studies suggest that this change can be done overnight without fearing new side effects development or deterioration of the previ - ously experienced side effects [ 102, 103, 107].”
BackgroundHosford, D. A., & Wang, Y. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01729.x · Cited by 150
van Vliet, E. A., Aronica, E., Redeker, S., Boer, K., & Gorter, J. A. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01727.x · Cited by 147 · cited 1×
“Furthermore, van Vliet et al. (2009) conducted a comparative study on the expres - sion of SV2A protein in resected temporal lobe specimens from patients with refractory epilepsy and in the hippocampi of rats subjected to experimental epileptogenesis by tetanic stimulation of the angular bundle.”
BackgroundVossler, D. G., Bainbridge, J. L., Boggs, J. G., Novotny, E. J., Loddenkemper, T., Faught, E., Amengual‐Gual, M., Fischer, S. N., Gloss, D. S., Olson, D. M., et al. (2020) · Epiliepsy currents/Epilepsy currents · doi:10.1177/1535759720928269 · Cited by 146
Margolis, J. M., Chu, B. C., Wang, Z. J., Copher, R. M., & Cavazos, J. E. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.808 · Cited by 136
Steinhoff, B. J., Klein, P., Klitgaard, H., Laloyaux, C., Moseley, B. D., Ricchetti-Masterson, K., Rosenow, F., Sirven, J. I., Smith, B. J., Stern, J. M., et al. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.107939 · Cited by 134 · cited 2×
“The side effect spectrum consists of irritability and aggres - sion and can be aggravated by psychosis, depression, and suicidal ideation [92].”
BackgroundHansen, C. C., Ljung, H., Brodtkorb, E., & Reimers, A. (2018) · Behavioural Neurology · doi:10.1155/2018/2064027 · Cited by 132 · cited 1×
“The mechanism that can underlie these effects might be related to the levetiracetam impact on the AMPA receptor [93].”
BackgroundLevetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131 · cited 3×
“At the post-synaptic level, it modulates the AMPA receptors [57].”
BackgroundInfluentialKaminski, R. M., Gillard, M. R., Leclercq, K., Hanon, É., Lorent, G., Dassesse, D., Matagne, A., & Klitgaard, H. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02089.x · Cited by 130 · cited 1×
“This assumption has been supported by the study performed by Kaminski et al. (2009), who showed that SV2A ( + / − ) heterozygous mice had a high sensitivity to seizures evoked by kainate, pilocarpine, PTZ, and 6-Hz electrical stimulation, but no such sensitivity was seen in the model of MES.”
ResultSynaptic vesicle protein 2A: basic facts and role in synaptic function
Mendoza‐Torreblanca, J. G., Vanoye‐Carlo, A., Phillips‐Farfán, B. V., Carmona‐Aparicio, L., & Gómez‐Lira, G. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12360 · Cited by 124
Genton, P., & Vleymen, B. V. (2000) · Epileptic Disorders · doi:10.1684/j.1950-6945.2000.tb00363.x · Cited by 123 · cited 1×
“Despite close structural similarities, various racetams have different phar - macological and clinical profiles [ 108].”
BackgroundSynaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123 · cited 1×
“Furthermore, although SV2A is localized at both inhibitory and excitatory synapses, and the expres - sion of SV2A is ubiquitous, stronger associations between SV2A and GABAergic rather than glutamatergic synapses were observed in some brain structures [50 ].”
BackgroundNew molecular targets for antiepileptic drugs: α2δ, SV2A, and Kv7/KCNQ/M potassium channels
Rogawski, M. A., & Bazil, C. W. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0053-7 · Cited by 119
Seizure freedom with more than one antiepileptic drug
Stephen, L. J., & Brodie, M. J. (2002) · Seizure · doi:10.1053/seiz.2002.0711 · Cited by 114
Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis
Tzellos, T., Toulis, K. A., Goulis, D. G., Papazisis, G., Zampeli, V., Vakfari, A., & Kouvelas, D. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01144.x · Cited by 112 · cited 2×
“…method, Czapinski et al. have found clinical evidence of the efficacy synergism and adverse symptoms antagonism in several combinations including gabapentin or levetiracetam: levetiracetam + lamotrigine, topiramate + levetiracetam, levetiracetam + oxcarbazepine, gabapentin + lamotrigine [147].”
MethodThe Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance
Stout, K. A., Dunn, A. R., Hoffman, C., & Miller, G. W. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00351 · Cited by 112
Wood, M. D., & Gillard, M. R. (2016) · Epilepsia · doi:10.1111/epi.13638 · Cited by 107 · cited 1×
“A radioligand binding study revealed that levetiracetam and brivarace-tam may interact differently with the SV2A protein bind - ing sites or interact with different conformational states of this protein [58].”
BackgroundBerdichevsky, Y., Dryer, A. M., Saponjian, Y., Mahoney, M. M., Pimentel, C., Lucini, C. A., Usenovic, M., & Staley, K. J. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3870-12.2013 · Cited by 105 · cited 1×
“Of note, both the oxidative stress and PI3K/Akt/mTOR path - way are also linked with molecular mechanisms of epilepto-genesis [124].”
BackgroundLöscher, W., & White, H. S. (2023) · Cells · doi:10.3390/cells12091233 · Cited by 98
Lamotrigine and topiramate may be a useful combination
Stephen, L. J., Sills, G. J., & Brodie, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(05)60613-7 · Cited by 95 · cited 1×
“A clinical method of assessing the value of a drug combination was proposed by Stephen et al. [160].”
MethodCuria, G., Biagini, G., Perucca, E., & Avoli, M. (2009) · CNS Drugs · doi:10.2165/00023210-200923070-00002 · Cited by 91
Kwan, P., Brodie, M. J., Kälviäinen, R. K., Yurkewicz, L., Weaver, J., & Knapp, L. E. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70154-5 · Cited by 88 · cited 1×
“In focal seizures, pregabalin has been found to be less beneficial than lamotrigine as the first-choice drug [148 ] and probably should not be used as the first-line ASM [97].”
BackgroundAntiepileptic drug combinations—Have newer agents altered clinical outcomes?
Stephen, L. J., Forsyth, M. G., Kelly, K., & Brodie, M. J. (2011) · Epilepsy Research · doi:10.1016/j.eplepsyres.2011.09.008 · Cited by 85 · cited 3×
“Clinical studies indicated that the two-drug combination of gabapentin with carbamazepine produced seizure freedom in 37 patients with focal and generalized seizures [158, 159].”
BackgroundInfluentialDevelopment and pharmacologic characterization of the rat 6 Hz model of partial seizures
Metcalf, C. S., West, P. J., Thomson, K. E., Edwards, S. F., Smith, M. D., White, H. S., & Wilcox, K. S. (2017) · Epilepsia · doi:10.1111/epi.13764 · Cited by 84 · cited 1×
“…as genetically sound-sensitive mice derived from a DBA strain and in the Genetic Absence Epilepsy Rats from the Strasbourg [77]; b– results from [167]; c– results from [66]; d– results from [168]; e– results from [133]; f– results from [130] other drugs which makes it a suitable medication for…”
ResultHirsch, M., Hintz, M., Specht, A., & Schulze‐Bonhage, A. (2018) · Seizure · doi:10.1016/j.seizure.2018.07.017 · Cited by 82 · cited 1×
“The optimal scheme in which the drugs should be replaced is not clear; however, the most frequently used ratio is 10:1 (for example, 1000 mg of levetiracetam is the equivalent of 100 mg of brivaracetam) or 15:1 [103, 106].”
BackgroundPharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice
Verrotti, A., Lattanzi, S., Brigo, F., & Zaccara, G. (2020) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2020.106939 · Cited by 82 · cited 1×
“Rational polytherapy should maximize the efficacy and minimize the side effects [ 153].”
BackgroundUpdate on Antiseizure Medications 2022
Abou-Khalil, B. W. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001104 · Cited by 82 · cited 4×
“However, levetiracetam is currently widely used both as the first-choice drug or add-on therapy for the treatment of focal seizures, myoclonias, and generalized tonic-clonic seizures [97].”
BackgroundInfluentialLevetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A
Nowack, A., Malarkey, E. B., Yao, J., Bleckert, A., Hill, J., & Bajjalieh, S. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029560 · Cited by 81
Prichard, K. L., O’Brien, N. S., Murcia, S. R., Baker, J. R., & McCluskey, A. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.754110 · Cited by 81
Tiagabine Synergistically Interacts with Gabapentin in the Electroconvulsive Threshold Test in Mice
Łuszczki, J. J., Świąder, M., Parada-Turska, J., & Czuczwar, S. J. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300243 · Cited by 71
Self-citationTreatment and care of women with epilepsy before, during, and after pregnancy: a practical guide
Nucera, B., Brigo, F., Trinka, E., & Kalss, G. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864221101687 · Cited by 71 · cited 1×
“Along with lamotrigine and oxcarbazepine, it is also one of the safest ASMs used in the treatment of women at the childbearing age, with the potential teratogenic effect within the range of the population risk of major congenital defects [86–88 ].”
BackgroundLevetiracetam has an activity‐dependent effect on inhibitory transmission
Meehan, A. L., Yang, X., Yuan, L., & Rothman, S. M. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2011.03392.x · Cited by 70
Borowicz, K. K., Świąder, M., Łuszczki, J. J., & Czuczwar, S. J. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.34301.x · Cited by 70
Self-citationSteinhoff, B. J., Bacher, M., Bucurenciu, I., Hillenbrand, B., Intravooth, T., Kornmeier, R., Kurth, C., Stockinger, J., & Staack, A. M. (2017) · Seizure · doi:10.1016/j.seizure.2017.03.010 · Cited by 70
Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels
Manville, R. W., & Abbott, G. W. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.112953 · Cited by 69 · cited 1×
“Thus, it was reported that gabapentin is a potent activator of the heteromeric KCNQ2/3 voltage-gated potassium channel and the homomeric KCNQ3 and KCNQ5 channels, whereas pre-gabalin at higher concentrations displays opposite effects [125].”
BackgroundŁuszczki, J. J., Andres‐Mach, M., Czuczwar, P., Cioczek‐Czuczwar, A., Ratnaraj, N., Patsalos, P. N., & Czuczwar, S. J. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00364.x · Cited by 67 · cited 2×
“However, based on type II isobolographic analysis, it was found that levetiracetam produced either synergistic or additive interactions with carbamazepine, oxcarbazepine, topiramate, felbamate, and retigabine in the mouse MES model [70–72 ].”
BackgroundMethodSelf-citationSynaptic vesicle protein 2: A multi-faceted regulator of secretion
Ciruelas, K., Marcotulli, D., & Bajjalieh, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.02.003 · Cited by 64 · cited 2×
“As pointed out by Ciruelas et al. (2019), since SV2A is the primary SV2 paralog in the majority of GABAergic neurons, reductions in its expres - sion could potentially contribute to the etiology of epilepsy and that precise control of SV2A expression is needed to prevent aberrant excitability [ 46].”
BackgroundIsobolographic profile of interactions between tiagabine and gabapentin: a preclinical study A,B
Łuszczki, J. J., & Czuczwar, S. J. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-004-0867-z · Cited by 63
Self-citationCharacterization of the Tetanus Toxin Model of Refractory Focal Neocortical Epilepsy in the Rat
Nilsen, K. E., Walker, M. C., & Cock, H. R. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.26004.x · Cited by 61
Gabapentin and Pregabalin for the Treatment of Anxiety Disorders
Greenblatt, H. K., & Greenblatt, D. J. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.446 · Cited by 60 · cited 3×
“Treatment with gabapentinoids also poses a risk of abuse and dependence, especially in patients abusing other drugs and substances in the past [142, 146].”
BackgroundPresynaptic α 2 δ subunits are key organizers of glutamatergic synapses
Schöpf, C. L., Ablinger, C., Geisler, S. M., Stanika, R. I., Campiglio, M., Kaufmann, W. A., Nimmervoll, B., Schlick, B., Brockhaus, J., Missler, M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920827118 · Cited by 60
Synergism of lacosamide with established antiepileptic drugs in the 6‐ H z seizure model in mice
Shandra, A. A., Shandra, P., Каshchenko, О. А., Matagne, A., & Stöhr, T. (2013) · Epilepsia · doi:10.1111/epi.12237 · Cited by 59
Yan, B. C., Wang, J., Rui, Y., Cao, J., Xu, P., Jiang, D., Zhu, X., Won, M., Bo, P., & Su, P. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly119 · Cited by 58
Zhou, M., Chen, S., Wang, L., Huang, Y., Deng, M., Zhang, J., Zhang, J., Chen, H., Yan, J., & Pan, H. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.0757-21.2021 · Cited by 57
Comparative efficacy of combination drug therapy in refractory epilepsy
Poolos, N. P., Warner, L. N., Humphreys, S. Z., & Williams, S. P. (2011) · Neurology · doi:10.1212/wnl.0b013e31823ed0dd · Cited by 55 · cited 1×
“In human clinical trials, the synergistic effect of only one combination of lamotrigine and valproate has been confirmed [ 155, 156].”
BackgroundIntravenous Brivaracetam in the Treatment of Status Epilepticus: A Systematic Review
Brigo, F., Lattanzi, S., Nardone, R., & Trinka, E. (2019) · CNS Drugs · doi:10.1007/s40263-019-00652-0 · Cited by 55
Neuronal α2δ proteins and brain disorders
Ablinger, C., Geisler, S. M., Stanika, R. I., Klein, C., & Obermair, G. J. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02420-2 · Cited by 54 · cited 1×
“Mutations and polymorphisms of human (CAC-NA2D1-4) genes encoding for the four known α2δ proteins (isoforms α2δ1 to α2δ4) are linked with several central ner - vous system disorders including epilepsy [116, 117].”
BackgroundWojda, E., Właź, A., Patsalos, P. N., & Łuszczki, J. J. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.06.003 · Cited by 53
Self-citationEarly add‐on treatmentvsalternative monotherapy in patients with partial epilepsy
Semah, F., Thomas, P., Coulbaut, S., & Derambure, P. (2014) · Epileptic Disorders · doi:10.1684/epd.2014.0650 · Cited by 52 · cited 1×
“Adjunctive therapy for epilepsy is preferred when the first antiepileptic drug is well tolerated and only partially effective, or the drug to be added to the therapy has not been tested in monotherapy [151].”
BackgroundLi, L., Chen, S., Zhou, M., Wang, L., Li, D., Chen, H., Lee, G., Jayaraman, V., & Pan, H. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109396 · Cited by 52 · cited 3×
“These results point to an important role of α2δ1 in modulating synaptic functions because the AMPA receptors which lack the GluA2 subunits are Ca 2 + -permeable and their presence is linked with some neurologic disorders [121].”
BackgroundInfluentialMolecular mechanisms of neurotransmitter release
Fon, E., & Edwards, R. (2001) · Muscle and Nerve · doi:10.1002/mus.1044 · Cited by 51 · cited 1×
“The molecular presynaptic events include the neurotransmitter cycle (biosynthesis, storage, reuptake, and degradation of neurotransmitters) and the synaptic vesicle cycle (targeting synaptic vesicles (SVs) to the nerve terminal and their docking, fusion, endocytosis, and recycling) [23].”
BackgroundBrivaracetam in the treatment of epilepsy: a review of clinical trial data
Feyissa, A. M. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s143548 · Cited by 51 · cited 3×
“Treatment with brivaracetam can, however, result in adverse events similar to these observed while administering levetirace-tam, among them are somnolence, fatigue, irritability, dizziness, insomnia, anxiety, and depression [ 98].”
BackgroundInfluentialNiespodziany, I., André, V., Leclère, N., Hanon, É., Ghisdal, P., & Wolff, C. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12347 · Cited by 49
A viewpoint on rational and irrational fixed-drug combinations
Błaszczyk, B., Miziak, B., Czuczwar, P., Wierzchowska-Cioch, E., Pluta, R. M., & Czuczwar, S. J. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1500895 · Cited by 48 · cited 1×
“This problem has been discussed in detail in a review by Błaszczyk et al. (2018) [ 162].”
MethodSelf-citationLeclercq, K., Matagne, A., Provins, L., Klitgaard, H., & Kaminski, R. M. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.261222 · Cited by 48
Taylor, C., & Harris, E. W. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.266056 · Cited by 48
Piracetam in the Treatment of Cortical Myoclonus
Centon, P., Guerrini, R., & Remy, C. (1999) · Pharmacopsychiatry · doi:10.1055/s-2007-979237 · Cited by 47
Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy
Celli, R., & Fornai, F. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200831154658 · Cited by 46 · cited 2×
“…and adhesion molecules (thrombospondins) inhibition of aberrant excitatory synaptogenesis analgesia, detrimental effect in the absence epilepsy [8, 120, 122] AMPAR controlling the subunit composition and Ca 2 + permeability of postsynaptic AMPARs analgesia [121] NMDAR interference with the…”
BackgroundLöscher, W., & Richter, A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00105-9 · Cited by 45 · cited 1×
“Of them, piracetam, aniracetam, oxiracetam, pramiracetam and phenylpiracetam show procognitive properties via positive allosteric modulation of the AMPA receptors, while levetiracetam, brivarace-tam, and seletracetam belong to ASMs [84 ] [Löscher and Richter, 2000].”
BackgroundWood, M. D., Daniëls, V., Provins, L., Wolff, C., Kaminski, R. M., & Gillard, M. R. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.261149 · Cited by 45
STXBP1 as a therapeutic target for epileptic encephalopathy
Stamberger, H., Weckhuysen, S., & Jonghe, P. D. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1386175 · Cited by 44
Ozsoy, H. Z. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03390-2 · Cited by 42
Tetanus neurotoxin–induced epilepsy in mouse visual cortex
Mainardi, M., Pietrasanta, M., Vannini, E., Rossetto, O., & Caleo, M. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03510.x · Cited by 40
Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis
Ohno, Y., & Tokudome, K. (2017) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527316666170404115027 · Cited by 40
Synaptopathies in Developmental and Epileptic Encephalopathies: A Focus on Pre-synaptic Dysfunction
Spoto, G., Valentini, G., Saia, M. C., Butera, A., Amore, G., Salpietro, V., Nicotera, A. G., & Rosa, G. D. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.826211 · Cited by 40 · cited 2×
“Hence, disturbances of mechanisms regulating the physiological synergy among presynaptic and postsynaptic components due to mutations of genes encoding some synaptic proteins lead to developmental and epileptic encephalopathies, known as “synaptopathies” [31].”
BackgroundTomson, T., Battino, D., Bromley, R., Kochen, S. S., Meador, K. J., Pennell, P. B., & Thomas, S. V. (2020) · Epilepsia Open · doi:10.1002/epi4.12420 · Cited by 39
Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography
Czuczwar, S. J., Kaplanski, J., Swiderska-Dziewit, G., Gergont, A., Kroczka, S., & Kaciński, M. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802677826 · Cited by 37 · cited 1×
“The isobolographic analysis of interactions is the best method employed in pharmacological and toxicologi - cal studies to classify the pharmacodynamic interactions between ASMs [81, 82].”
MethodSelf-citationPregabalin monotherapy in patients with partial-onset seizures: A historical-controlled trial
French, J. A., Kwan, P., Fakhoury, T. A., Pitman, V. W., Dubrava, S., Knapp, L. E., & Yurkewicz, L. (2014) · Neurology · doi:10.1212/wnl.0000000000000119 · Cited by 37 · cited 1×
“However, the results of the study in which the conversion of previous treatment to pregabalin monotherapy was assessed were favorable for the drug [149].”
ResultDudra-Jastrzębska, M., Andres‐Mach, M., Sielski, M., Ratnaraj, N., Patsalos, P. N., Czuczwar, S. J., & Łuszczki, J. J. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.12.046 · Cited by 35
Self-citationWu, P.-P., Cao, B.-R., Tian, F.-Y., & Gao, Z.-B. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-023-01138-2 · Cited by 35
Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities
Theochari, E. G., Cock, H. R., Lozsádi, D. A., Galtrey, C. M., Arevalo, J., & Mula, M. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.11.032 · Cited by 34
GABAergic circuits drive focal seizures
Dossi, E., & Huberfeld, G. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106102 · Cited by 33 · cited 1×
“The deficit in the inhibi - tory processes is predominantly linked with insufficiency in GABA A receptor-mediated neurotransmission [10].”
BackgroundŁuszczki, J. J., Andres‐Mach, M., Ratnaraj, N., Patsalos, P. N., & Czuczwar, S. J. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2006.00964.x · Cited by 32
Self-citationAsadi‐Pooya, A. A., Sperling, M. R., Chung, S. S., Klein, P., Diaz, A., Elmoufti, S., Schiemann, J., & Whitesides, J. (2017) · Epilepsy Research · doi:10.1016/j.eplepsyres.2017.02.007 · Cited by 32
Upregulated dynamin 1 in an acute seizure model and in epileptic patients
Li, Y., Chen, X., Fan, X., Zhang, Y., Gu, J., Fu, X., Wang, Z., Wang, X., & Xiao, Z. (2014) · Synapse · doi:10.1002/syn.21788 · Cited by 28
Therapy for hyperthermia-induced seizures in Scn1a mutant rats
Hayashi, K., Ueshima, S., Ouchida, M., Mashimo, T., Nishiki, T., Sendo, T., Serikawa, T., Matsui, H., & Ohmori, I. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03046.x · Cited by 28 · cited 1×
“Gabapentin has been reported to decrease the duration of hyperthermia-induced seizures in Scn1a mutant rats [127] but had no significant effect on seizure frequency in the lethargic (lh/lh) mouse model of absence seizures [128].”
BackgroundŁuszczki, J. J., Ratnaraj, N., Patsalos, P. N., & Czuczwar, S. J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.07.051 · Cited by 28
Self-citationDudra-Jastrzębska, M., Andres‐Mach, M., Ratnaraj, N., Patsalos, P. N., Czuczwar, S. J., & Łuszczki, J. J. (2009) · Seizure · doi:10.1016/j.seizure.2009.06.009 · Cited by 28
Self-citationOkada, M., Fukuyama, K., Shiroyama, T., & Ueda, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111462 · Cited by 28
Metcalf, C. S., Klein, B. D., Smith, M. D., Pruess, T., Ceusters, M., Lavreysen, H., Pype, S., Osselaer, N. V., Twyman, R. E., & White, H. S. (2017) · Epilepsia · doi:10.1111/epi.13659 · Cited by 26 · cited 1×
“…of patients in which levetiracetam had to be discontinued due JNJ-40,411,813, and LY-404,039 (four positive allosteric modulators of the metabotropic glutamate receptor subtype 2) resulted in supra-additive interactions in the mouse 6 Hz corneal stimulation-induced (44 mA) seizure model [79, 80].”
Gáll, Z., Kelemen, K., Tolokán, A., Zolcseak, I., Sável, I., Bod, R.-B., Ferencz, E., Vancea, S., Urkon, M., & Kolcsár, M. (2022) · Biomedicines · doi:10.3390/biomedicines10081811 · Cited by 26
Łuszczki, J. J., & Czuczwar, S. J. (2005) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-005-1088-9 · Cited by 25 · cited 1×
“In the mouse PTZ-induced seizure model, gabapentin produced synergistic interactions with vigabatrin [131 ] and oxcarbazepine [ 132], and an additive interaction with tiagabine [133], felbamate, and loreclezole [134].”
BackgroundSelf-citationMetcalf, C. S., Klein, B. D., Smith, M. D., Ceusters, M., Lavreysen, H., Pype, S., Osselaer, N. V., Twyman, R. E., & White, H. S. (2018) · Epilepsia · doi:10.1111/epi.14005 · Cited by 24
Łuszczki, J. J., Andres‐Mach, M., & Czuczwar, S. J. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.03.046 · Cited by 23 · cited 1×
“In the mouse PTZ-induced seizure model, gabapentin produced synergistic interactions with vigabatrin [131 ] and oxcarbazepine [ 132], and an additive interaction with tiagabine [133], felbamate, and loreclezole [134].”
BackgroundSelf-citationŁuszczki, J. J., Filip, D., & Czuczwar, S. J. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.07.009 · Cited by 23
Self-citationFukuyama, K., & Okada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094473 · Cited by 22
Isobolographic analysis of the mechanisms of action of anticonvulsants from a combination effect
Matsumura, N., & Nakaki, T. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.08.001 · Cited by 21 · cited 1×
“The isobolographic analysis of interactions is the best method employed in pharmacological and toxicologi - cal studies to classify the pharmacodynamic interactions between ASMs [81, 82].”
MethodŁuszczki, J. J., Mazurkiewicz, L. P., Wróblewska-Łuczka, P., Właź, A., Ossowska, G., Szpringer, M., Żółkowska, D., & Florek-Łuszczki, M. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.06.003 · Cited by 20
Self-citationSynaptic Vesicles Dynamics in Neocortical Epilepsy
Vannini, E., Restani, L., Dilillo, M., McDonnell, L. A., Caleo, M., & Marra, V. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.606142 · Cited by 17 · cited 1×
“Furthermore, Vannini et al. (2020) showed in the mouse model of neocortical epilepsy induced by Tetanus neurotoxin an early-onset lengthening of active zones at inhibitory synapses and a delayed spatial reorganization of recycled vesicles at excitatory synapses [34].”
BackgroundHung, T., Wu, S., & Huang, C. (2021) · Biomedicines · doi:10.3390/biomedicines9040369 · Cited by 17
Bradberry, M. M., & Chapman, E. R. (2022) · The Journal of Physiology · doi:10.1113/jp282601 · Cited by 16 · cited 1×
“[29].”
Zhang, Y., Heylen, L., Partoens, M., Mills, J. D., Kaminski, R. M., Godard, P., Gillard, M. R., de Witte, P. A. M., & Siekierska, A. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.881933 · Cited by 16 · cited 2×
“Both valproate and, surprisingly, levetiracetam partially reduced the epileptiform activity, which suggests that besides SV2A, other mechanisms may be involved in the antiepileptic effects of levetiracetam [ 61].”
BackgroundMethodBotermans, W., Koole, M. J. B., Laere, K. V., Savidge, J. R., Kemp, J. A., Sunaert, S. G., Duffy, M. M., Ramael, S., Cesura, A. M., D’Ostilio, K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1066447 · Cited by 16
Łuszczki, J. J., Zagaja, M. P., Miziak, B., Florek-Łuszczki, M., & Czuczwar, S. J. (2015) · Pharmacology · doi:10.1159/000430822 · Cited by 15 · cited 2×
“However, based on type II isobolographic analysis, it was found that levetiracetam produced either synergistic or additive interactions with carbamazepine, oxcarbazepine, topiramate, felbamate, and retigabine in the mouse MES model [70–72 ].”
BackgroundMethodSelf-citationOvernight switch from levetiracetam to brivaracetam. Safety and tolerability
Abraira, L., Salas‐Puig, J., Quintana, M., Seijo‐Raposo, I., Santamarina, E., Fonseca, E., & Toledo, M. (2021) · Epilepsy & Behavior Reports · doi:10.1016/j.ebr.2021.100504 · Cited by 14 · cited 3×
“The optimal scheme in which the drugs should be replaced is not clear; however, the most frequently used ratio is 10:1 (for example, 1000 mg of levetiracetam is the equivalent of 100 mg of brivaracetam) or 15:1 [103, 106].”
BackgroundResultSV2A in Epilepsy: The Plot Thickens
Sills, G. J. (2010) · Epiliepsy currents/Epilepsy currents · doi:10.1111/j.1535-7511.2009.01351.x · Cited by 13 · cited 1×
“The intriguing hypothesis addressing a possible relationship between a lowered SV2A expression and the progressive nature of the resultant epi - leptic state has been questioned and needs further evidence [47]. synaptic transmission.”
BackgroundEffects of piracetam alone and in combination with antiepileptic drugs in rodent seizure models
Fischer, W., Kittner, H., Regenthal, R., Russo, E., & Sarro, G. D. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0155-6 · Cited by 13
Antiepileptic Drugs and Their Dual Mechanism of Action on Carbonic Anhydrase
Magheru, C., Magheru, S., Coltąu, M., Hoza, A., Moldovan, C. M., Sachelarie, L., Grădinaru, I., Hurjui, L. L., Marc, F., & Farcaș, D. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092614 · Cited by 13 · cited 1×
“…such as acetazolamide, topiramate, and zonisamide, restore the equilibrium among CO 2 , H + , and HCO 3 − , reduce the NMDA-mediated excitation, potentiate the GABA A R-mediated inhibition, and affect the activity of ligand-gated Ca 2 + channels and voltage-gated Ca 2 + channels (VGCC) [17, 18].”
BackgroundŁuszczki, J. J., Filip, D., & Florek-Łuszczki, M. (2011) · Epilepsy Research · doi:10.1016/j.eplepsyres.2011.09.002 · Cited by 12
Self-citationGe, Y.-X., Lin, Y.-Y., Bi, Q., & Chen, Y. (2020) · Current Neurovascular Research · doi:10.2174/1567202617666200514114917 · Cited by 12
Łuszczki, J. J., Panasiuk, A., Zagaja, M. P., Karwan, S., Bojar, H., Plewa, Z., & Florek-Łuszczki, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234070 · Cited by 12 · cited 8×
“Pregabalin combined with gabapentin produced an additive interaction in the mouse 6 Hz corneal stimulation-induced (32 mA) seizure model [77], but the same two-drug combination triggered a synergistic interaction in the mouse MES model [130].”
BackgroundMethodResultInfluentialSelf-citationBleakley, L. E., McKenzie, C. E., & Reid, C. A. (2022) · Epilepsia · doi:10.1111/epi.17447 · Cited by 11 · cited 1×
“Of new genetic models, recent data showed that levetirace-tam significantly reduced ECoG spike frequency medication in a mouse model of potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) developmental and epileptic encephalopathy [69].”
Łuszczki, J. J. (2010) · Advances in Medical Sciences · doi:10.2478/v10039-010-0005-8 · Cited by 10
Self-citationZałuska-Ogryzek, K., Marzęda, P., Wróblewska-Łuczka, P., Florek-Łuszczki, M., Plewa, Z., Bojar, H., Żółkowska, D., & Łuszczki, J. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115537 · Cited by 9 · cited 2×
“…oxcarbazepine, and pregabalin with phenobarbital and topiramate [140], pre-gabalin with lacosamide and topiramate, pregabalin with lacosamide and oxcarbazepine, pregabalin with oxcarbaze - pine and topiramate [141 ], all the six combinations evoked synergistic interactions in the mouse MES model.”
BackgroundMethodSelf-citationŁuszczki, J. J., Podgórska, D., Kozińska, J., Jankiewicz, M., Plewa, Z., Kominek, M., Żółkowska, D., & Florek-Łuszczki, M. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00164-5 · Cited by 8
Self-citationPathophysiological Roles of Auxiliary Calcium Channel α2δ Subunits
Hessenberger, M., Haddad, S., & Obermair, G. J. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2022_630 · Cited by 8 · cited 1×
“Mutations and polymorphisms of human (CAC-NA2D1-4) genes encoding for the four known α2δ proteins (isoforms α2δ1 to α2δ4) are linked with several central ner - vous system disorders including epilepsy [116, 117].”
BackgroundOdell, L. R., Jones, N. C., Chau, N., Robertson, M. J., Ambrus, J. I., Deane, F. M., Young, K. A., Whiting, A., Xue, J., Prichard, K. L., et al. (2023) · RSC Medicinal Chemistry · doi:10.1039/d2md00371f · Cited by 8 · cited 1×
“More recently, a new class of GTP-competitive dyna - min inhibitors which inhibit dynamin I GTPase and clath - rin-mediated endocytosis showed a significant anti-seizure activity in a 6 Hz mouse psychomotor seizure test [38].”
BackgroundSANAD II: Dear Levetiracetam, the Honeymoon Is Over
Bermeo-Ovalle, A. C. (2021) · Epiliepsy currents/Epilepsy currents · doi:10.1177/15357597211052129 · Cited by 6
Syntaxin 7 modulates seizure activity in epilepsy
Wu, J., Zhang, H., Yang, L., Chen, Y., Li, J., Yang, M., Zhang, X., He, C., Wang, X., & Xu, X. P. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106118 · Cited by 5
Xing, H., Han, X., Xu, S., Sun, Z., & Yang, S. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-01983-2 · Cited by 4
Metcalf, C. S., Gagangras, S., Bulaj, G. W., & White, H. S. (2022) · Epilepsia · doi:10.1111/epi.17420 · Cited by 3
Poster Session 2�11:00 a.m.-7:30 p.m.�Professionals in Epilepsy care
(2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01871_7.x · Cited by 2
Cited by
The neuroplastic brain: current breakthroughs and emerging frontiers
Gazerani, P. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149643 · Cited by 174
“…2022; Jannati et al., 2023; Suppa et al., 2022; Lefaucheur et al., 2020). o Transcranial Direct Current Stimulation (tDCS): tDCS can induce long-term changes in neuronal excitability (Lang et al., 2004), facilitating motor and cognitive recovery in stroke and neuropsychiatric disorders…”
Plants, Pills, and the Brain: Exploring Phytochemicals and Neurological Medicines
Aggarwal, A., Rajalekshmi, R., Aggarwal, A., & Agrawal, D. K. (2025) · International Journal of Plant Animal and Environmental Sciences · doi:10.26502/ijpaes.4490180 · Cited by 8
“Levetiracetam’s precise binding to SV2A facilitates broad-spectrum seizure control with minimal drug-drug interactions, making it a preferred option for both monotherapy and adjunctive use [43,44].”
Epilepsy: Epidemiology, Molecular Pathogenesis, and Clinical Management
Liu, J., Wu, X., Yin, T., Huang, F., Kong, M., Yang, Y., Liu, Z. H., Yu, J., & Zhang, T. (2026) · MedComm · doi:10.1002/mco2.70837 · Cited by 5
Supportive pain therapy in dermatology
Werner, M., Stromer, W., Hüning, S., Loquai, C., Kähler, K. C., Susok, L., & Nashan, D. (2025) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15624 · Cited by 1
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Metadata
- Authors
- Czapińska-Ciepiela, E. K., Łuszczki, J., Czapiński, P., Czuczwar, S. J., & Lasoń, W.
- Affiliations
- Medical University of Lublin (PL)
- Maj Institute of Pharmacology (PL)
- Corresponding author
- Lasoń, Władysław
- Venue
- Pharmacological Reports
- Published
- 2024-05-22
- Volume
- 76
- Issue
- 4
- Pages
- 623-643
- ISSN
- 1734-1140 (ISSN-L)
- 2299-5684
- PMC
- PMC11294404
- OpenAlex
- W4398219983
- Cited by
- 13
- References
- 166
- Citations by year
- 2026: 10 · 2025: 3
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Pharmacological Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- levetiracetam, brivaracetam, pregabalin, gabapentin, α2δ-1 subunit, voltage-gated calcium channels, epilepsy, drug-resistant epilepsy, combination therapy
- MeSH terms
- Animals, Anticonvulsants, Epilepsy, Humans, Calcium Channels, Presynaptic Terminals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.